|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
0.75/0.98
|
企业价值
10.37B
|
资产负债 |
每股账面净值
12.28
|
现金流量 |
现金流量率
0.09
|
损益表 |
收益
4.44B
|
每股收益
8.80
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|

同行比较之报价最少15分钟延迟
业务概览
|
|||
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal productsused in cattle, sheep, goats, and swine production. |